Table 2.
Anticancer activities IC50 (μM) of 10-substituted 3,6-diazaphenothiazines (1b–4f) against glioblastoma SNB-19, colorectal carcinoma Caco-2, lung cancer A549, breast cancer MDA-MB231 cells and normal human fibroblasts NHDF.
| No | Anticancer Activity IC50 (μM) | ||||
|---|---|---|---|---|---|
| SNB-19 | Caco-2 | A549 | MDA-MB231 | NHDF | |
| 1b | 69.15+/−3.14 | 19.92+/-2.71 | >100 | 13.66+/−1.16 | >100 |
| 1c | 5.72+/−1.44 | 8.10+/−0.92 | 29.12+/−2.59 | 7.82+/−1.32 | >100 |
| 1d | 4.66+/−1.16 | 0.25+/−0.02 | 0.25+/−0.01 | 0.51+/−0.09 | >100 |
| 1e | 9.65+/−1.99 | 79.65+/−4.12 | 1.79+/−0.62 | 25.79+/−1.32 | >100 |
| 1f | >100 | >100 | >100 | 68.68+/−5.12 | >100 |
| 2b | 41.91+/−3.15 | >100 | 77.44+/−3.22 | 56.34+/−5.72 | >100 |
| 2c | 55.23+/−5.78 | 43.61+/−6.52 | 60.23+/−2.77 | 9.21+/−3.01 | >100 |
| 2d | 59.87+/−9.99 | 11.42+/−2.13 | 1.82+/−0.71 | 4.71+/−0.22 | 42.95+/−5.11 |
| 2e | 10.62+/−1.11 | 34.38+/−2.72 | 63.75+/−2.78 | 12.04+/−2.21 | >100 |
| 2f | 56.34+/−5.72 | 32.55+/−8.21 | 46.80+/−2.73 | 12.04+/−6.11 | >100 |
| 3b | 2.04+/−0.21 | 0.26+/−0.01 | 0.26+/−0.11 | 0.77+/−0.10 | 22.66+/−1.32 |
| 3c | 57.92+/−4.96 | 29.87+/−5.21 | 27.23+/−2.16 | 25.66+/−4.11 | 70.61+/−12.21 |
| 3d | 31.31+/−10.99 | 33.07+/−9.18 | 17.91+/−1.11 | 4.26+/−0.15 | >100 |
| 3e | 26.80+/−1.72 | 10.02+/−0.99 | 30.07+/−3.21 | 3.50+/−0.35 | 49.47+/−1.11 |
| 3f | 32.58+/−2.77 | 14.54+/−1.22 | 0.65+/−0.10 | 0.64+/−0.10 | 52.90+/−3.21 |
| 4b | 20.80+/−1.96 | 57.90+/−2.15 | 60.62+/−3.52 | 7.87+/−1.11 | >100 |
| 4c | 6.25+/−0.62 | 0.25+/−0.02 | 0.25+/−0.01 | 1.97+/−0.13 | 2.85+/−0.34 |
| 4d | 14.87+/−1.70 | 42.06+/−2.99 | 53.99+/−10.72 | 13.44+/−1.22 | >100 |
| 4e | 53.62+/−3.72 | 74.28+/−4.72 | 42.69+/−13.72 | 38.77+/−2.12 | >100 |
| 4f | 44.83+/−13.62 | 67.52+/−11.87 | >100 | 44.33+/−11.79 | >100 |
| Cisplatin | 3.73+/−0.62 | 10.53+/−1.52 | 0.60+/−0.11 | 3.13+/−0.24 | 63.87+/−1.32 |